XML 50 R39.htm IDEA: XBRL DOCUMENT v3.19.1
Asterias Merger (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Mar. 08, 2019
Mar. 08, 2019
Sep. 30, 2018
Mar. 31, 2019
Mar. 31, 2018
May 08, 2019
Dec. 31, 2018
May 13, 2016
Closing price of common stock       $ 162,844     $ 93,840  
Number of warrants issued to purchase of common stock               2,813,159
Fair value of warrants       $ (37) $ 108      
Common stock held in investment 2,621,811 2,621,811            
Share price, per share $ 1.31 $ 1.31         $ 0.62  
Fair value of Equity method investment, shares       21,700        
Fair value of Equity method investment, value $ 20,200 $ 20,200         $ 13,500  
General and Administrative [Member]                
Acquisition related costs       $ 3,500        
April, 2019 [Member]                
Number of warrants issued to purchase of common stock       907,442        
Fair value of warrants       $ 372        
Common Stock [Member]                
Number of warrants issued to purchase of common stock               2,959,559
Exercise price               $ 4.37
Warrant term               5 years
Warrant expiration date               May 13, 2021
BioTime Warrants [Member]                
Exercise price       $ 6.15        
Warrant expiration date       May 31, 2021        
Fair value of warrants       $ 495        
AST Clinical Program [Member]                
Identifiable intangible asset acquired   46,500            
Royalty Contracts [Member]                
Useful life of asset       5 years        
In Process Research and Development [Member]                
Identifiable intangible asset acquired   31,700            
Regenerative Medicine [Member]                
Identifiable intangible asset acquired   $ 14,800            
30 Days After the Closing of Asterian Merger [Member] | BioTime Warrants [Member]                
Number of warrants issued to purchase of common stock       1,089,900        
December 31, 2018 to March 8, 2019 [Member]                
Unrealized loss       $ 6,700        
December 31, 2017 to March 31, 2018 [Member]                
Unrealized loss         $ 17,400      
December 31, 2017 to March 31, 2018 [Member] | Maximum [Member]                
Share price, per share         $ 2.25      
December 31, 2017 to March 31, 2018 [Member] | Minimum [Member]                
Share price, per share         $ 1.45      
Parent Company [Member]                
Number of warrants issued to purchase of common stock       1,997,340        
Parent Company [Member] | April, 2019 [Member]                
Fair value of warrants       $ 332        
Exchange of shares       251,835        
Exchange for cash       $ 40        
Asterias [Member]                
Upfront payment received     $ 1,000          
Estimated purchase price     $ 200          
Ownership interest       38.00%        
Merger Consideration [Member] | Parent Company [Member]                
Stock-for-stock transaction 24,695,898 24,695,898            
Closing price of common stock           $ 32,400    
Merger Consideration [Member] | Asterias [Member]                
Stock-for-stock transaction 0.71 0.71            
Merger Consideration [Member] | Asterias [Member] | Restricted Stock [Member]                
Stock-for-stock transaction 58,085 58,085